PharmaPoint: Epilepsy – Global Drug Forecast and Market Analysis to 2026
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. Seizures result from abnormal electrical discharges in the brain and vary in their manifestations, from the brief staring spells that are characteristic of absence seizures, to full-body convulsions known as tonic-clonic seizure. Epilepsy can be considered a spectrum disorder due to its different causes, different seizure types, and different disease severities.
There are several anti-epileptic drugs (AEDs) on the market, with an older generation fully genericized across the 7MM (US, France, Germany, Italy, Spain, UK and, Japan) and a second generation, which are patent protected. There are five drugs in the late stage pipeline, which address some of the unmet needs in the market and, as such are expected to drive growth while patent expiries for major brand are expected to act as a barrier to growth for the epilepsy market over the forecast period.
GlobalData estimates that drug sales for epilepsy in 2016 were approximately $6.1 billion across the seven major markets covered in this report. Over the 10-year forecast period, the market is expected to grow to $7.5 billion at a CAGR of 2.1%. This growth will be driven by the launch of five late-stage pipeline products. The two highest selling drugs are expected to be GW Pharmaceuticals’ Epidiolex (cannabidiol) and Zogenix’s flenfluramine, which both target rare, orphan epilepsy syndrome, are forecast to be the top selling pipeline drugs in the forecast period.
Scope
Overview of epilepsy, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
Annualized epilepsy therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (focal, generalized, and unclassified seizures) forecast from 2016 to 2026.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the epilepsy therapeutics market
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for epilepsy therapy. The most promising candidates in Phase III development are profiled.
Analysis of the current and future market competition in the global epilepsy therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global epilepsy therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global epilepsy therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Zogenix
UCB
Upsher-Smith Laboratories
Neurelis
Lundbeck
Sanofi
Pfizer
SK Biopharmaceuticals
Supernus Pharmaceuticals
Daiichi-Sankyo
Brabant Pharma
Eisai
Novartis
GlaxoSmithKline
Alfresa Pharma
Bial – Portela & CA
S.A
Ligand Pharmaceuticals
Aprecia Pharmaceuticals
Dainippon Sumitomo
Concordia
Sepracor (Sunovion Pharmaceuticals)
Mylan Pharmaceuticals
Glenmark Pharmaceuticals
Ovation Pharmaceuticals
Teva
Allergan
Twi Pharmaceuticals
Zydus
Cadila Healthcare
Catalyst Pharmaceuticals
Cadila Healthcare
Catalyst Pharmaceuticals
inVentiv Health
Janssen
Par Pharmaceuticals
Argentum Pharmaceuticals
Abbot
Valeant Pharmaceuticals
CURx Pharmaceuticals
Admas Pharmaceuticals
Greenwich Biosciences
Aegis Therapeutics
Roche
Shire
Ikano Therapeutics
Alexza Pharmaceuticals
Zynerba Pharmaceuticals
Monosol Rx
Marinus Pharmaceuticals
Johnson & Johnson
PTC Therapeutics
INSYS Therapeutics
Anavex Life Sciences
VistaGen Therapeutics
BioHealthonomics
Biscayne Pharmaceuticals
MMU PhytoTech
Bio-Pharm Solutions
Suda
Marathon Pharmaceuticals
Takeda
Idorsia
Otsuka
CuroNZ
Mucodel Pharma
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.